Sharath Hegde, Ph.D., is an experienced Executive with over 30 years of leadership experience in strategic and tactical aspects of drug-discovery and early clinical development. Since 2019, Sharath has played the role of Chief Scientific Officer at Recursion, a digital biology company. Prior to joining Recursion, Sharath spent 19 years at Theravance Biopharma where he was Senior Vice President and Head of Research. Before Theravance, Sharath spent 9 years at Syntex Corporation, later acquired by Roche Holdings, Ltd. Dr. Hegde obtained his Ph.D. in Pharmacology from the University of Houston and obtained his B.Pharm/M.Pharm degree in Pharmacy/Pharmacology from the University of Mumbai in India. He has participated in the discovery of over 16 clinical-stage molecules including the marketed medicines Vibativ® (telavancin), Yupelri® (revefenancin) and several others in late stage development. Sharath has been trained in classical pharmacology, and possesses extensive experience in drug discovery across multiple therapeutic areas including infectious, cardiovascular, respiratory, genitourinary, gastrointestinal, neurology, fibrosis, oncology, autoimmune and inflammatory diseases. He is the co-author of over 50 scientific publications and has served on the Editorial Board of several journals.